Evaluation of Probiotics In Prevention Of Fungal Infection (Candida) in Sick Children in IC
Not Applicable
Not yet recruiting
- Conditions
- Health Condition 1: null- Sepsis
- Registration Number
- CTRI/2011/11/002172
- Lead Sponsor
- ICMR Applied for
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 240
Inclusion Criteria
All patients admitted to PICU who has received broad spectrum antibiotics for a
minimum of 48 hours
Exclusion Criteria
1. Known immunodeficiency states
2. Immunosuppressive therapy
3. Child on prior antifungal therapy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms do probiotics use to prevent candidemia in septic pediatric ICU patients?
How effective are probiotics compared to antifungal prophylaxis in preventing fungal infections in critically ill children?
Which biomarkers correlate with probiotic efficacy in sepsis-associated candidemia prevention?
What are the safety profiles and adverse event management strategies for probiotic use in pediatric sepsis cases?
Are there combination therapies involving probiotics and antifungals that improve outcomes in septic ICU children?